Active Stocks
Fri Apr 12 2024 15:57:45
  1. Tata Steel share price
  2. 163.50 -1.00%
  1. NTPC share price
  2. 362.00 -0.32%
  1. ITC share price
  2. 430.10 -1.56%
  1. HDFC Bank share price
  2. 1,518.90 -1.10%
  1. State Bank Of India share price
  2. 766.75 -1.57%
Business News/ Industry / Manufacturing/  Cadila, Depomed settle US patent dispute on neuro pain drug Gralise
BackBack

Cadila, Depomed settle US patent dispute on neuro pain drug Gralise

Cadila can now launch its generic version of Gralise in the US soon after the expiry of Depomed's original patent

A file photo of Cadila Healthcare chairman Pankaj Patel. Photo: S.Kumar/ MintPremium
A file photo of Cadila Healthcare chairman Pankaj Patel. Photo: S.Kumar/ Mint

Mumbai: Ahmedabad-based drug maker Cadila Healthcare Ltd said on Tuesday that it has settled a patent infringement case with US drug maker Depomed Inc., ending a litigation related to Depomed’s neuropathic pain drug Gralise.

With this settlement, the Indian company can launch its generic version of Gralise, also known as gabapentin, in the US market soon after the expiry of Depomed’s original patent in February 2024 or even before that under the terms of the agreement.

Depomed posted sales of $36.2 million in 2013 for Gralise.

Shares of Cadila Healthcare closed at 976.851, up 1.03% on Tuesday, while the benchmark Sensex closed down 0.64% at 22,484.93 points.

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Industry News, Banking News and Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
More Less
Published: 15 Apr 2014, 11:45 AM IST
Next Story footLogo
Recommended For You
Manufacturing Stocks
₹601.95-0.73%
ITC
₹436.9-1.56%
₹2,958.6-0.79%
₹165.15-1%
Switch to the Mint app for fast and personalized news - Get App